Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
67.22
-2.41 (-3.46%)
At close: Nov 6, 2025, 4:00 PM EST
66.75
-0.47 (-0.70%)
After-hours: Nov 6, 2025, 5:13 PM EST
Exact Sciences Revenue
Exact Sciences had revenue of $850.74M in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $3.08B, up 14.47% year-over-year. In the year 2024, Exact Sciences had annual revenue of $2.76B with 10.37% growth.
Revenue (ttm)
$3.08B
Revenue Growth
+14.47%
P/S Ratio
4.09
Revenue / Employee
$440,290
Employees
7,000
Market Cap
12.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EXAS News
- 2 days ago - These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga
- 2 days ago - Exact Sciences to Participate in November Investor Conference - Business Wire
- 2 days ago - Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Exact Sciences Announces Third Quarter 2025 Results - Business Wire
- 10 days ago - Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps - Business Wire
- 4 weeks ago - Exact Sciences Schedules Third Quarter 2025 Earnings Call - Business Wire
- 4 weeks ago - New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies - Business Wire
- 6 weeks ago - Exact Sciences' Clear Expansion Path: Why Choose To Buy - Seeking Alpha